Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years ...Middle East

PR Newswire - News
Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years
TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial DUBLIN and SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year...

Hence then, the article about medtronic evolut tavr platform outperforms surgery with sustained valve performance for low risk patients at four years was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News